This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sensus Healthcare, Inc. (SRTS) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Here's Why Momentum in Sensus Healthcare (SRTS) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sensus Healthcare (SRTS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
by Zacks Equity Research
Here is how Sensus Healthcare, Inc. (SRTS) and Aileron Therapeutics, Inc. (ALRN) have performed compared to their sector so far this year.
Zacks.com featured highlights include Sensus Healthcare, Diebold Nixdorf, Adtalem Global Education, Dycom Industries and Superior Group
by Zacks Equity Research
Sensus Healthcare, Diebold Nixdorf, Adtalem Global Education, Dycom Industries and Superior Group are part of the Zacks Screen of the Week article.
5 Stocks With Recent Price Strength That Have More Upside Left
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are SRTS, DBD, ATGE, DY, SGC.
Here's What Could Help Sensus Healthcare (SRTS) Maintain Its Recent Price Strength
by Zacks Equity Research
Sensus Healthcare (SRTS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for February 12th
by Zacks Equity Research
MSGE, AZEK, XRX, AMSC and SRTS have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2023.
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 116.67% and 3.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Surges 12.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 60% and 7.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare (SRTS) Expands Global Base With New Pact
by Zacks Equity Research
The agreement includes the distribution of Sensus Healthcare's (SRTS) SRT-100, SRT-100+ and SR-100 Vision systems, specifically designed for the treatment of non-melanoma skin cancer and keloids.
CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
CVRx (CVRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -209.09% and 63.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 7.14% and 1.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 6.10% and 7.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Sensus Healthcare (SRTS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sensus Healthcare (SRTS) stock based on the movements in the options market lately.
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -34.62% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Sensus Healthcare, Inc. (SRTS) Have the Potential to Rally 81.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Sensus Healthcare, Inc. (SRTS) points to an 81.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 72.6% Upside in Sensus Healthcare, Inc. (SRTS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 72.6% upside potential for Sensus Healthcare, Inc. (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down 46.9% in 4 Weeks, Here's Why Sensus Healthcare, Inc. (SRTS) Looks Ripe for a Turnaround
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sensus Healthcare, Inc. (SRTS) Q3 Earnings Lag Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -8.33% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?